Greth Warren, Robbie Gabriel J, Brohawn Philip, Hultquist Micki, Yao Bing
MedImmune, Gaithersburg, MD, USA.
Immunotherapy. 2017 Jan;9(1):57-70. doi: 10.2217/imt-2016-0090.
Dysregulation of the type I interferon (IFN) system is associated with various immunologic diseases, such as systemic lupus erythematosus (SLE). Targeting this dysregulation presents an attractive approach for SLE therapy. Sifalimumab, a fully human immunoglobulin G κ monoclonal antibody that binds to and neutralizes most IFN-α subtypes, has been recently evaluated in a Phase IIb study in patients with moderate to severe SLE. Insights gained from earlier studies were used to inform design of the Phase IIb study, to provide a more comprehensive evaluation of sifalimumab. Sifalimumab demonstrated broad efficacy across composite and organ-specific end points, suggesting that targeting of IFN-α is a promising treatment option for SLE, particularly for those patients whose disease is refractory to current standard of care.
I型干扰素（IFN）系统失调与多种免疫疾病相关，如系统性红斑狼疮（SLE）。针对这种失调情况是SLE治疗的一种有吸引力的方法。西法莫单抗是一种完全人源化的免疫球蛋白Gκ单克隆抗体，可结合并中和大多数IFN-α亚型，最近在一项针对中重度SLE患者的IIb期研究中进行了评估。早期研究获得的见解被用于指导IIb期研究的设计，以对西法莫单抗进行更全面的评估。西法莫单抗在综合和器官特异性终点方面均显示出广泛疗效，这表明靶向IFN-α是SLE的一种有前景的治疗选择，特别是对于那些对当前标准治疗难治的患者。
